Trevi Therapeutics (TRVI) Total Current Liabilities (2018 - 2026)

Trevi Therapeutics' Total Current Liabilities history runs 9 years deep, the most recent figure standing at $7.1 million for Q1 2026.

• In Q1 2026, Total Current Liabilities rose 3.63% year-over-year to $7.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 3.63% YoY), while the FY2025 annual figure was $9.7 million, down 7.23% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $7.1 million, down from $9.7 million in the prior quarter.
• The five-year high for Total Current Liabilities was $15.4 million in Q2 2022, with the low at $4.7 million in Q2 2023.
• The 5-year median for Total Current Liabilities is $9.1 million (2024), against an average of $9.3 million.
• The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 141.05% in 2022, then sank 69.47% in 2023.
• Trevi Therapeutics' Total Current Liabilities stood at $13.4 million in 2022, then slumped by 56.54% to $5.8 million in 2023, then soared by 80.44% to $10.5 million in 2024, then fell by 7.23% to $9.7 million in 2025, then decreased by 27.02% to $7.1 million in 2026.
• Business Quant data shows TRVI's Total Current Liabilities at $7.1 million in Q1 2026, $9.7 million in Q4 2025, and $9.0 million in Q3 2025.